<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5F9516A3-2B98-4823-8A23-AFEADBB1FB4D"><gtr:id>5F9516A3-2B98-4823-8A23-AFEADBB1FB4D</gtr:id><gtr:firstName>Susan</gtr:firstName><gtr:otherNames>E</gtr:otherNames><gtr:surname>Shapiro</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701372"><gtr:id>DC054740-43A3-4E5D-8417-D8990870BFDE</gtr:id><gtr:title>The role of N-linked glycans in mediating Factor VIII - von Willebrand factor binding and their functional consequences.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701372</gtr:grantReference><gtr:abstractText>Factor VIII (FVIII) and von Willebrand factor (VWF) are proteins essential for normal blood clotting. They are particularly important because their levels are extremely variable; high levels are associated with an increased tendency to clot and low levels with increased risk of bleeding (affecting approximately 1% of the population). Because they circulate in the blood as a tightly linked complex, they depend on one another for survival and function. Consequently the degree to which they bind to each other is important. Understanding this binding is important for understanding the associated diseases. If we could manipulate this interaction it would be an extremely useful therapeutic tool. 
The sugar content of VWF has recently emerged as an important factor in determining the structure and function of VWF. We have preliminary evidence that it may affect this important binding between VWF and FVIII. Thus this project will examine the effect of sugars, and other structures, on FVIII-VWF binding. This knowledge will improve our understanding of the associated bleeding disorders, and may help improve existing therapies. In particular it may allow the development of recombinant FVIII and VWF molecules which are more effective, have prolonged survival (meaning fewer injections), fewer side effects and complications.</gtr:abstractText><gtr:technicalSummary>Background
Factor VIII (FVIII) and von Willebrand factor (VWF) are plasma proteins essential for normal haemostasis. Their physiology is closely intertwined because they circulate in plasma as a tight non-covalently linked complex. This interaction has a major effect on their survival, function, and immune presentation. Moreover because the Kd for the FVIII-VWF interaction is close to the plasma concentration of FVIII a significant proportion of plasma FVIII is unbound. This will alter its survival, interaction with other molecules, procoagulant capacity and presentation by the immune system: all important therapeutic effects. Current available literature indicates that the interactions between the two molecules are incompletely understood. This laboratory has identified N-linked glycosylation as a previously unexplored component of the interaction. Haemophilia A and von Willebrand disease (VWD) are now treatable with recombinant products, but these are not identical to plasma-derived FVIII and VWF and may differ significantly in their glycosylation. Such differences, possibly acting via modification of the FVIII-VWF interaction, may be responsible for assay discrepancies, variable efficacy and differential success in immune tolerance with recombinant FVIII preparations. 
Aims
To determine the role of VWF N-linked glycans in the FVIII-VWF interaction and their functional consequences. 
Objectives
1. To determine the effects of differing VWF glycan structures on FVIII binding; either via specific binding or effects on conformation.
2. To determine the sugar binding capacity of the FVIII light chain. 
3. To define the effects of altered FVIII light chain structure on VWF binding.
4. To quantify the effects of these interactions and their modification on FVIII procoagulant function.
Design and Methodology
The FVIII-VWF interaction will be studied using a combination of full length plasma-derived VWF and FVIII, recombinant VWF and FVIII (full length and domains), glycosidase-modified plasma-derived VWF, and recombinant VWF with N-linked glycosylation removed by site-directed mutagenesis. The molecular basis of the interaction will be established using the techniques of plate-based binding assays, surface plasmon resonance and lectin columns. The functional consequences of the interaction will be assessed using thrombin generation assays (with both phospholipids vesicles and platelets).
Scientific and Medical Opportunities
Better definition of the FVIII-VWF interaction will improve our understanding of the pathogenesis of bleeding in haemophilia A and VWD which in turn may improve diagnosis and use of existing therapies. It will also enable manipulation of the interaction to allow development of therapeutic FVIII-VWF molecules with increased efficacy, longer effective half-life, and decreased immunogenicity.</gtr:technicalSummary><gtr:fund><gtr:end>2013-06-25</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-05-26</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>208235</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>47C5BF31-1AD2-4DDD-A72E-F4C8890534CF</gtr:id><gtr:title>Potential thiol isomerase activity of conserved CXXC motifs in D3, D4 and C1 domains of von Willebrand factor</gtr:title><gtr:parentPublicationTitle>JOURNAL OF THROMBOSIS AND HAEMOSTASIS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64a6b0b0fe5e3096637a04790d5c206f"><gtr:id>64a6b0b0fe5e3096637a04790d5c206f</gtr:id><gtr:otherNames>Shapiro S. E.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1538-7933</gtr:issn><gtr:outcomeId>Q7mH2HmsRYU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E1B73D7-14C9-4125-B033-EB7A7160BDC6</gtr:id><gtr:title>The Effect of Unpaired Cysteine Residues and the C Domains On the Expression of Von Willebrand Factor</gtr:title><gtr:parentPublicationTitle>BLOOD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85824efb15fde2221bbaa46271d737f4"><gtr:id>85824efb15fde2221bbaa46271d737f4</gtr:id><gtr:otherNames>Mckinnon Thomas A. J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>tY3qTwJSmn1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D60DF52E-569F-49FF-8510-EB25F0B1D18B</gtr:id><gtr:title>Analysis of protein disulphide isomerase motifs (CXXC) in mature von Willebrand factor.</gtr:title><gtr:parentPublicationTitle>British Society of Haemostasis and Thrombosis, AGM oral presentation 2012</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48fd5770e0867f567a99fb413afb1c72"><gtr:id>48fd5770e0867f567a99fb413afb1c72</gtr:id><gtr:otherNames>Shapiro Susan</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>hYcGn5r2bCY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C34D7E96-6830-4EBD-97CB-282489B64FA0</gtr:id><gtr:title>The von Willebrand factor predicted unpaired cysteines are essential for secretion.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b93f3b4743726eebf7aba4aa6c5cfa18"><gtr:id>b93f3b4743726eebf7aba4aa6c5cfa18</gtr:id><gtr:otherNames>Shapiro SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>pm_540e158e158353760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D31C6267-F5E1-4111-B1A9-A59DF473E60B</gtr:id><gtr:title>The C domains and certain predicted unpaired cysteines of von Willebrand factor are essential for its secretion</gtr:title><gtr:parentPublicationTitle>British Society of Haemostasis and Thrombosis, AGM oral presentation 2012. Top scoring abstract from a Scientist-in-Training</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48fd5770e0867f567a99fb413afb1c72"><gtr:id>48fd5770e0867f567a99fb413afb1c72</gtr:id><gtr:otherNames>Shapiro Susan</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>Pg38CX5jNJw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5289C746-650B-467F-9106-8C8DE66439B4</gtr:id><gtr:title>Nine predicted unpaired cysteine residues in von Willebrand factor are essential for VWF secretion</gtr:title><gtr:parentPublicationTitle>BRITISH JOURNAL OF HAEMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64a6b0b0fe5e3096637a04790d5c206f"><gtr:id>64a6b0b0fe5e3096637a04790d5c206f</gtr:id><gtr:otherNames>Shapiro S. E.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>YDo6Ppf8W9T</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701372</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>